Bioventus Operating Expenses 2018-2025 | BVS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Bioventus operating expenses from 2018 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Bioventus operating expenses from 2018 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$75.3B
Zoetis (ZTS)	$68.1B
Takeda Pharmaceutical (TAK)	$46.9B
Daiichi Sankyo, - (DSNKY)	$43.1B
BeOne Medicines - (ONC)	$29.6B
Sandoz Group AG (SDZNY)	$25B
Summit Therapeutics (SMMT)	$18.1B
Merck (MKKGY)	$16.5B
Shionogi (SGIOY)	$14.2B
United Therapeutics (UTHR)	$13.2B
Neurocrine Biosciences (NBIX)	$13B
Orion OYJ (ORINY)	$11B
IPSEN (IPSEY)	$10.2B
Stevanato Group S.p.A (STVN)	$7.8B
Corcept Therapeutics (CORT)	$7.6B
Madrigal Pharmaceuticals (MDGL)	$6.9B
Grifols, S.A (GRFS)	$6.7B
Ionis Pharmaceuticals (IONS)	$6.7B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Ono Pharmaceutical (OPHLF)	$5.3B
Soleno Therapeutics (SLNO)	$4.2B
Hypermarcas (HYPMY)	$3.2B
Crinetics Pharmaceuticals (CRNX)	$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.6B
NewAmsterdam Pharma (NAMS)	$2.4B
Centessa Pharmaceuticals (CNTA)	$2B
BioCryst Pharmaceuticals (BCRX)	$1.8B
Ocular Therapeutix (OCUL)	$1.8B
ARS Pharmaceuticals (SPRY)	$1.7B